Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
31 studies found for:    " January 24, 2009":" February 23, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" January 24, 2009":" February 23, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV
Conditions: HIV;   HIV Infections
Interventions: Biological: ZFN modified T cells;   Other: Structured Treatment Interruption
2 Completed Video-based Counseling & Rapid HIV Testing for Teens
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Video;   Behavioral: in-person HIV pre-test counseling
3 Completed A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
Conditions: HIV-1;   HIV Infections
Interventions: Biological: V520;   Biological: Comparator: V520 (1x10^9 vp/d);   Biological: Comparator: V520 (1x10^10 vp/d);   Biological: Comparator: Placebo
4 Completed
Has Results
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Conditions: HIV-1;   HIV Infections
Interventions: Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine;   Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose);   Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
5 Completed Positive Lifestyles Using Safety
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Pre-Release (Group 1);   Behavioral: Post-release (Group 2)
6 Unknown  A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication
Conditions: HIV-1;   HIV Infections
Interventions: Other: VircoType HIV-1 genotypic interpretation;   Other: Local Expert Review of HIV Genotypic resistance testing
7 Completed
Has Results
Behavioral Intervention to Reduce Sexual and Injection Risks Among Female Sex Workers Who Also Inject Drugs in Mexico
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Interactive injection and sexual risk intervention;   Behavioral: Interactive Sexual Risk Intervention;   Behavioral: Interactive Injection Risk Intervention
8 Completed
Has Results
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
Condition: HIV Infections
Interventions: Other: Placebo;   Biological: TUTI-16 (0.03mg);   Biological: TUTI-16 (0.1mg);   Biological: TUTI-16 (0.6mg)
9 Completed ID and Testing Via Friendship Networks
Conditions: Asymptomatic HIV;   HIV Infections
Interventions: Other: Index Recruiter;   Other: Friendship Network Member
10 Completed A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
Conditions: HIV;   HIV Infections
Intervention:
11 Completed
Has Results
Exercise, Oxidative Stress and HIV
Condition: HIV Infections
Intervention:
12 Completed Study of Impacts of Food Supplementation on Malnourished HIV-Infected Adults in Kenya
Conditions: HIV;   Malnutrition;   HIV Infections
Interventions: Dietary Supplement: fortified blended flour - Insta Foundation Plus (with whey protein concentrate);   Other: nutrition counseling
13 Completed
Has Results
A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
Conditions: HIV-1 Infection;   HIV Infections
Interventions: Biological: mRNA-transfected autologous dendritic cells;   Biological: autologous dendritic cells with no mRNA transfection
14 Completed Cell Phone Intervention to Support Antiretroviral Therapy (ART) Adherence in Kenya
Conditions: HIV;   AIDS;   HIV Infections
Intervention: Other: Cell Phone Intervention
15 Unknown  Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring
Conditions: Human Immunodeficiency Virus;   HIV Infections
Interventions: Drug: Reducing dose of Lopinavir;   Drug: Reducing dose of efavirenz
16 Completed Transitions: Linkages From Jail To Community
Conditions: HIV;   Substance Abuse;   HIV Infections
Intervention: Behavioral: Intensive Case Management
17 Completed
Has Results
Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
Conditions: Human Immunodeficiency Virus Type 1 (HIV-1);   HIV Infections
Interventions: Drug: Voriconazole;   Drug: Atazanavir;   Drug: Ritonavir
18 Unknown  Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
Conditions: HIV;   Hyperlipidemia;   HIV Infections
Interventions: Drug: ezetimibe;   Drug: fenofibrate;   Drug: pravastatin
19 Completed Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.
Conditions: HIV-1 Infection;   HIV Infections
Intervention: Drug: darunavir
20 Completed Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa
Conditions: Cryptococcal Meningitis;   HIV Infections
Interventions: Drug: Fluconazole;   Drug: Fixed dose - Stavudine, lamivudine and Nevirapine;   Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.